FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1489437124> ?p ?o ?g. }

• W1489437124 abstract "Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CAFatty acid synthase (FASN) expression increases with tumor progression and is associated with impaired response to chemotherapy and diminished patient survival in many solid and hematopoietic tumor types. Palmitate, the product of FASN enzymatic activity, functions in vital cellular processes including energy metabolism and cell growth, cellular membrane biosynthesis and architecture, and protein localization and function. 3-V Biosciences has discovered and developed a series of potent, selective, orally available, and reversible FASN inhibitors with excellent pharmaceutical properties. Single agent FASN inhibition has been shown to cause anti-tumor activities in preclinical models of human cancer, including inhibition of AKT and mTOR signal transduction, induction of tumor cell apoptosis, and tumor growth inhibition and regression in pancreatic, ovarian, and lung cancer xenograft tumor models of human cancer. Current studies are supporting the active clinical development of TVB-2640, 3-V Biosciences' first-in-class FASN inhibitor, as an oncology therapeutic. These studies have multiple objectives: (1) characterizing a wide range of tumor types for responsiveness to FASN inhibition using tumor cell line and Champions TumorGraftTM efficacy models; (2) investigating the benefit of FASN combination therapy with chemotherapeutic or targeted anti-cancer agents; (3) developing biomarkers that characterize efficacy response; and (4) further elucidating the mechanisms of action that emanate from the inhibition of palmitate synthesis and lead to tumor cell apoptosis and in vivo anti-tumor efficacy. The results of these investigations show that FASN inhibition causes tumor growth inhibition or regression in diverse tumor types; and moreover, that tumor growth inhibition additivity or synergy is observed when FASN inhibition is combined with chemotherapy agents. Genomics and directed analysis of mRNA, proteins, and lipids following FASN inhibition have identified biomarker candidates and provided insights into the tumor growth inhibition mechanisms of action. For example, genome-wide gene expression analysis shows FASN inhibition to significantly increase the expression of many genes in biosynthetic (sterol, lipid, etc.) and apoptosis pathways while significantly reducing the expression of many genes in cell growth and proliferation pathways (DNA replication, cell cycle progression, mitosis, etc.). These data strongly support the clinical development of TVB-2640 as a first-in-class single and combination oncology therapeutic and are advancing the discovery and validation of biomarkers to inform clinical utility and response.Citation Format: Timothy S. Heuer, Richard Ventura, Joanna Waszczuk, Kasia Mordec, Julie Lai, Russell Johnson, Lilly Hu, Haiying Cai, Allan Wagman, Douglas Buckley, Stanley T. Parish, Elizabeth Bruckheimer, George Kemble. Efficacy of FASN-selective small molecule inhibitors in preclinical tumor models. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 1815. doi:10.1158/1538-7445.AM2014-1815" @default.
• W1489437124 created "2016-06-24" @default.
• W1489437124 creator A5020414960 @default.
• W1489437124 creator A5020667709 @default.
• W1489437124 creator A5023527864 @default.
• W1489437124 creator A5025154671 @default.
• W1489437124 creator A5028584676 @default.
• W1489437124 creator A5031221350 @default.
• W1489437124 creator A5037704297 @default.
• W1489437124 creator A5043145184 @default.
• W1489437124 creator A5045051767 @default.
• W1489437124 creator A5063172780 @default.
• W1489437124 creator A5064076137 @default.
• W1489437124 creator A5084919600 @default.
• W1489437124 creator A5086374199 @default.
• W1489437124 date "2014-09-30" @default.
• W1489437124 modified "2023-09-27" @default.
• W1489437124 title "Abstract 1815: Efficacy of FASN-selective small molecule inhibitors in preclinical tumor models" @default.
• W1489437124 doi "https://doi.org/10.1158/1538-7445.am2014-1815" @default.
• W1489437124 hasPublicationYear "2014" @default.
• W1489437124 type Work @default.
• W1489437124 sameAs 1489437124 @default.
• W1489437124 citedByCount "0" @default.
• W1489437124 crossrefType "proceedings-article" @default.
• W1489437124 hasAuthorship W1489437124A5020414960 @default.
• W1489437124 hasAuthorship W1489437124A5020667709 @default.
• W1489437124 hasAuthorship W1489437124A5023527864 @default.
• W1489437124 hasAuthorship W1489437124A5025154671 @default.
• W1489437124 hasAuthorship W1489437124A5028584676 @default.
• W1489437124 hasAuthorship W1489437124A5031221350 @default.
• W1489437124 hasAuthorship W1489437124A5037704297 @default.
• W1489437124 hasAuthorship W1489437124A5043145184 @default.
• W1489437124 hasAuthorship W1489437124A5045051767 @default.
• W1489437124 hasAuthorship W1489437124A5063172780 @default.
• W1489437124 hasAuthorship W1489437124A5064076137 @default.
• W1489437124 hasAuthorship W1489437124A5084919600 @default.
• W1489437124 hasAuthorship W1489437124A5086374199 @default.
• W1489437124 hasConcept C121608353 @default.
• W1489437124 hasConcept C126322002 @default.
• W1489437124 hasConcept C150903083 @default.
• W1489437124 hasConcept C190283241 @default.
• W1489437124 hasConcept C207001950 @default.
• W1489437124 hasConcept C4733338 @default.
• W1489437124 hasConcept C48289651 @default.
• W1489437124 hasConcept C502942594 @default.
• W1489437124 hasConcept C55493867 @default.
• W1489437124 hasConcept C71924100 @default.
• W1489437124 hasConcept C86554907 @default.
• W1489437124 hasConcept C86803240 @default.
• W1489437124 hasConcept C98274493 @default.
• W1489437124 hasConceptScore W1489437124C121608353 @default.
• W1489437124 hasConceptScore W1489437124C126322002 @default.
• W1489437124 hasConceptScore W1489437124C150903083 @default.
• W1489437124 hasConceptScore W1489437124C190283241 @default.
• W1489437124 hasConceptScore W1489437124C207001950 @default.
• W1489437124 hasConceptScore W1489437124C4733338 @default.
• W1489437124 hasConceptScore W1489437124C48289651 @default.
• W1489437124 hasConceptScore W1489437124C502942594 @default.
• W1489437124 hasConceptScore W1489437124C55493867 @default.
• W1489437124 hasConceptScore W1489437124C71924100 @default.
• W1489437124 hasConceptScore W1489437124C86554907 @default.
• W1489437124 hasConceptScore W1489437124C86803240 @default.
• W1489437124 hasConceptScore W1489437124C98274493 @default.
• W1489437124 hasLocation W14894371241 @default.
• W1489437124 hasOpenAccess W1489437124 @default.
• W1489437124 hasPrimaryLocation W14894371241 @default.
• W1489437124 hasRelatedWork W1430013678 @default.
• W1489437124 hasRelatedWork W1516070730 @default.
• W1489437124 hasRelatedWork W1594473529 @default.
• W1489437124 hasRelatedWork W1777295695 @default.
• W1489437124 hasRelatedWork W2017399995 @default.
• W1489437124 hasRelatedWork W2058182609 @default.
• W1489437124 hasRelatedWork W2068101665 @default.
• W1489437124 hasRelatedWork W2089617164 @default.
• W1489437124 hasRelatedWork W2168347591 @default.
• W1489437124 hasRelatedWork W2333039840 @default.
• W1489437124 hasRelatedWork W2335544039 @default.
• W1489437124 hasRelatedWork W2403105944 @default.
• W1489437124 hasRelatedWork W2403817921 @default.
• W1489437124 hasRelatedWork W2504955763 @default.
• W1489437124 hasRelatedWork W2741659768 @default.
• W1489437124 hasRelatedWork W2745695523 @default.
• W1489437124 hasRelatedWork W2765487040 @default.
• W1489437124 hasRelatedWork W2804842024 @default.
• W1489437124 hasRelatedWork W2891421071 @default.
• W1489437124 hasRelatedWork W290575242 @default.
• W1489437124 isParatext "false" @default.
• W1489437124 isRetracted "false" @default.
• W1489437124 magId "1489437124" @default.
• W1489437124 workType "article" @default.